

Safety, tolerability, and immunogenicity of two Zika virus vaccines in healthy adults: randomised, open-label, phase 1 clinical trial

Lancet, The

391, 552-562

DOI: [10.1016/s0140-6736\(17\)33105-7](https://doi.org/10.1016/s0140-6736(17)33105-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. <i>Nature Communications</i> , 2018, 9, 673.	5.8	84
2	Cellular and Humoral Immunity Protect against Vaginal Zika Virus Infection in Mice. <i>Journal of Virology</i> , 2018, 92, .	1.5	54
3	The countermeasure for Zika virus: a hard nut to be cracked. <i>Future Virology</i> , 2018, 13, 361-369.	0.9	1
4	Tradition and innovation in development of a Zika vaccine. <i>Lancet, The</i> , 2018, 391, 516-517.	6.3	3
5	Recent Advances in Zika Virus Vaccines. <i>Viruses</i> , 2018, 10, 631.	1.5	36
6	Fast Tracks and Roadblocks for Zika Vaccines. <i>Vaccines</i> , 2018, 6, 77.	2.1	7
7	Chronicling the Risk and Risk Communication by Governmental Officials During the Zika Threat. <i>Risk Analysis</i> , 2018, 38, 2507-2513.	1.5	7
8	Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine. <i>Scientific Reports</i> , 2018, 8, 18017.	1.6	33
9	An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections. <i>Cell Reports</i> , 2018, 25, 3382-3392.e3.	2.9	79
10	The Many Faces of a Dynamic Virion: Implications of Viral Breathing on Flavivirus Biology and Immunogenicity. <i>Annual Review of Virology</i> , 2018, 5, 185-207.	3.0	49
11	Assay Challenges for Emerging Infectious Diseases: The Zika Experience. <i>Vaccines</i> , 2018, 6, 70.	2.1	4
12	A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission. <i>Cell Host and Microbe</i> , 2018, 24, 487-499.e5.	5.1	46
13	A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates. <i>Frontiers in Immunology</i> , 2018, 9, 2464.	2.2	36
14	Zika Virus Vaccines: Challenges and Perspectives. <i>Vaccines</i> , 2018, 6, 62.	2.1	17
15	Developing Zika vaccines: the lessons for disease X. <i>Genome Medicine</i> , 2018, 10, 47.	3.6	9
16	A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity. <i>EBioMedicine</i> , 2018, 36, 92-102.	2.7	37
17	In silico approaches to Zika virus drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 825-835.	2.5	9
18	The emergence of Zika virus and its new clinical syndromes. <i>Nature</i> , 2018, 560, 573-581.	13.7	303

#	ARTICLE	IF	CITATIONS
19	Zika Virus Vaccine: Progress and Challenges. <i>Cell Host and Microbe</i> , 2018, 24, 12-17.	5.1	81
20	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018, 9, 2441.	5.8	69
21	Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein. <i>Npj Vaccines</i> , 2018, 3, 29.	2.9	38
22	Expression of a Zika virus antigen in microalgae: Towards mucosal vaccine development. <i>Journal of Biotechnology</i> , 2018, 282, 86-91.	1.9	36
23	A VSV-based Zika virus vaccine protects mice from lethal challenge. <i>Scientific Reports</i> , 2018, 8, 11043.	1.6	63
24	A Review of DNA Vaccines Against Influenza. <i>Frontiers in Immunology</i> , 2018, 9, 1568.	2.2	80
25	Role of Zika Virus prM Protein in Viral Pathogenicity and Use in Vaccine Development. <i>Frontiers in Microbiology</i> , 2018, 9, 1797.	1.5	39
26	Prevention and Control Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector Mosquitoesâ€”Current Updates. <i>Frontiers in Microbiology</i> , 2018, 9, 87.	1.5	39
27	Development of Zika Virus Vaccines. <i>Vaccines</i> , 2018, 6, 7.	2.1	24
28	Zika virus vaccines: immune response, current status, and future challenges. <i>Current Opinion in Immunology</i> , 2018, 53, 130-136.	2.4	45
29	Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. <i>PLoS ONE</i> , 2018, 13, e0202820.	1.1	45
30	New Vaccine Technologies to Combat Outbreak Situations. <i>Frontiers in Immunology</i> , 2018, 9, 1963.	2.2	437
31	Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. <i>Npj Vaccines</i> , 2018, 3, 24.	2.9	76
32	Zika virus vaccines. <i>Nature Reviews Microbiology</i> , 2018, 16, 594-600.	13.6	98
33	Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection. <i>Antiviral Research</i> , 2019, 170, 104578.	1.9	15
34	Zika Vaccine Developmentâ€”Current Progress and Challenges for the Future. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 104.	0.9	21
35	Immunological Assays used to Support Efficacy of Zika Virus Vaccines. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 97.	0.9	3
36	Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice. <i>Journal of Infectious Diseases</i> , 2019, 220, 1577-1588.	1.9	39

#	ARTICLE	IF	CITATIONS
37	Capsid containing virus like particle vaccine against Zika virus made from a stable cell line. <i>Vaccine</i> , 2019, 37, 7123-7131.	1.7	15
38	Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine. <i>Vaccines</i> , 2019, 7, 161.	2.1	16
39	ZIKV infection induces robust Th1-like Tfh cell and long-term protective antibody responses in immunocompetent mice. <i>Nature Communications</i> , 2019, 10, 3859.	5.8	39
40	A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy. <i>Cell Reports</i> , 2019, 28, 2634-2646.e4.	2.9	19
41	Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go. <i>Pharmaceuticals</i> , 2019, 12, 127.	1.7	11
42	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. <i>PLoS ONE</i> , 2019, 14, e0222178.	1.1	18
43	UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments. <i>Vaccine</i> , 2019, 37, 6241-6247.	1.7	13
44	Virus-Like Particle Systems for Vaccine Development Against Viruses in the Flaviviridae Family. <i>Vaccines</i> , 2019, 7, 123.	2.1	11
45	A "Furry-Tale" of Zika Virus Infection: What Have We Learned from Animal Models?. <i>Viruses</i> , 2019, 11, 29.	1.5	20
46	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	6.6	85
47	Using Macaques to Address Critical Questions in Zika Virus Research. <i>Annual Review of Virology</i> , 2019, 6, 481-500.	3.0	27
48	Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy. <i>Journal of Virology</i> , 2019, 93, .	1.5	32
49	Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 68.	0.9	11
50	Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein. <i>Journal of Virology</i> , 2019, 93, .	1.5	12
51	Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome. <i>Nature Communications</i> , 2019, 10, 1943.	5.8	44
52	A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. <i>Vaccines</i> , 2019, 7, 37.	2.1	266
53	Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. <i>Vaccine</i> , 2019, 37, 2122-2130.	1.7	16
54	Zika virus during pregnancy: From maternal exposure to congenital Zika virus syndrome. <i>Prenatal Diagnosis</i> , 2019, 39, 420-430.	1.1	54

#	ARTICLE	IF	CITATIONS
55	Identification of relevant regions on structural and nonstructural proteins of Zika virus for vaccine and diagnostic test development: an in silico approach. <i>New Microbes and New Infections</i> , 2019, 29, 100506.	0.8	9
56	Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus. <i>MBio</i> , 2019, 10, .	1.8	57
57	Pre-Clinical Pregnancy Models for Evaluating Zika Vaccines. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 58.	0.9	6
58	Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 91.	1.8	10
59	Identification of small molecule inhibitors targeting the Zika virus envelope protein. <i>Antiviral Research</i> , 2019, 164, 147-153.	1.9	14
60	Antimalarial drugs and their metabolites are potent Zika virus inhibitors. <i>Journal of Medical Virology</i> , 2019, 91, 1182-1190.	2.5	36
61	HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. <i>Nature Communications</i> , 2019, 10, 798.	5.8	61
62	Simian Immunodeficiency Virus Infection of Rhesus Macaques Results in Delayed Zika Virus Clearance. <i>MBio</i> , 2019, 10, .	1.8	4
63	Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas. <i>Emerging Infectious Diseases</i> , 2019, 25, 2191-2196.	2.0	3
64	DNA vaccination before conception protects Zika virus-exposed pregnant macaques against prolonged viremia and improves fetal outcomes. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	31
65	Strategies for inducing effective neutralizing antibody responses against HIV-1. <i>Expert Review of Vaccines</i> , 2019, 18, 1127-1143.	2.0	23
66	Zika Vaccine Development: Current Status. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2572-2586.	1.4	69
67	Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007978.	1.3	9
68	NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice. <i>Science Advances</i> , 2019, 5, eaax2388.	4.7	64
69	Maternal vaccination and protective immunity against Zika virus vertical transmission. <i>Nature Communications</i> , 2019, 10, 5677.	5.8	32
70	Zika Virus Vaccine Development: Progress in the Face of New Challenges. <i>Annual Review of Medicine</i> , 2019, 70, 121-135.	5.0	76
71	Zika Vaccines. , 2019, , 75-88.		0
72	Drugs for the Treatment of Zika Virus Infection. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 470-489.	2.9	63

#	ARTICLE	IF	CITATIONS
73	Inhibitors of the Zika virus protease NS2B-NS3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126965.	1.0	56
74	Zika virus. , 2020, , 289-319.		0
75	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Cancers</i> , 2020, 12, 2831.	1.7	12
76	Soil-Transmitted Helminth Vaccines: Are We Getting Closer?. <i>Frontiers in Immunology</i> , 2020, 11, 576748.	2.2	34
77	Contemporary Understanding of Ebola and Zika Virus in Pregnancy. <i>Clinics in Perinatology</i> , 2020, 47, 835-846.	0.8	3
78	Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection. <i>EBioMedicine</i> , 2020, 61, 103028.	2.7	10
79	Immunopathology of Zika virus infection. <i>Advances in Virus Research</i> , 2020, 107, 223-246.	0.9	0
80	A Glimmer of Hope: Recent Updates and Future Challenges in Zika Vaccine Development. <i>Viruses</i> , 2020, 12, 1371.	1.5	20
81	NS1-based DNA vaccination confers mouse protective immunity against ZIKV challenge. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104521.	1.0	7
82	A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding a secreted spike protein portion. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1874-1878.	0.9	29
83	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. <i>Science Advances</i> , 2020, 6, eaba5068.	4.7	50
84	Cutaneous vaccination ameliorates Zika virus-induced neuro-ocular pathology via reduction of anti-ganglioside antibodies. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2072-2091.	1.4	5
85	Zika vaccine pre-clinical and clinical data review with perspectives on the future development. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2524-2536.	1.4	11
86	Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model. <i>Vaccine</i> , 2020, 39, 4903-4913.	1.7	10
87	Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines. <i>Vaccines</i> , 2020, 8, 481.	2.1	10
88	Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in <i>Escherichia coli</i> . <i>Vaccines</i> , 2020, 8, 492.	2.1	18
89	Viral Emerging Diseases: Challenges in Developing Vaccination Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 2130.	2.2	77
90	Current Flavivirus Research Important for Vaccine Development. <i>Vaccines</i> , 2020, 8, 477.	2.1	2

#	ARTICLE	IF	CITATIONS
91	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. <i>Frontiers in Medical Technology</i> , 2020, 2, 571030.	1.3	29
92	Vaccines for COVID-19. <i>Clinical and Experimental Immunology</i> , 2020, 202, 162-192.	1.1	185
93	Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation. <i>Nature Communications</i> , 2020, 11, 2421.	5.8	6
94	Reverse genetic approaches for the development of Zika vaccines and therapeutics. <i>Current Opinion in Virology</i> , 2020, 44, 7-15.	2.6	3
95	Preparedness of public health-care system for Zika virus outbreak: An Indian perspective. <i>Journal of Infection and Public Health</i> , 2020, 13, 949-955.	1.9	9
96	Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. <i>Future Drug Discovery</i> , 2020, 2, FDD25.	0.8	1
97	Current Status of Zika Virus Vaccines: Successes and Challenges. <i>Vaccines</i> , 2020, 8, 266.	2.1	79
98	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	30
99	The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization. <i>Expert Review of Vaccines</i> , 2020, 19, 175-194.	2.0	16
100	An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques. <i>Npj Vaccines</i> , 2020, 5, 19.	2.9	14
101	Immune responses and protective effects against Japanese encephalitis induced by a DNA vaccine encoding the prM/E proteins of the attenuated SA14-14-2 strain. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104443.	1.0	7
102	Characterization of a Species E Adenovirus Vector as a Zika virus vaccine. <i>Scientific Reports</i> , 2020, 10, 3613.	1.6	15
103	Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine. <i>Vaccines</i> , 2020, 8, 69.	2.1	4
104	Understanding Flavivirus Capsid Protein Functions: The Tip of the Iceberg. <i>Pathogens</i> , 2020, 9, 42.	1.2	34
105	COVID-19 vaccines: breaking record times to first-in-human trials. <i>Npj Vaccines</i> , 2020, 5, 34.	2.9	92
106	Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections. <i>Frontiers in Immunology</i> , 2020, 11, 592.	2.2	34
107	Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade. <i>Frontiers in Microbiology</i> , 2020, 11, 362.	1.5	9
108	The biomedical and bioengineering potential of protein nanocompartments. <i>Biotechnology Advances</i> , 2020, 41, 107547.	6.0	25

#	ARTICLE	IF	CITATIONS
109	DNA vaccines: prime time is now. <i>Current Opinion in Immunology</i> , 2020, 65, 21-27.	2.4	123
110	Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses. <i>Vaccine</i> , 2020, 38, 3653-3664.	1.7	17
111	A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7981-7989.	3.3	24
112	Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design. <i>Frontiers in Immunology</i> , 2020, 11, 517.	2.2	31
113	Zika virus – an update on the current efforts for vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 904-908.	1.4	7
114	Zika virus pathogenesis and current therapeutic advances. <i>Pathogens and Global Health</i> , 2021, 115, 21-39.	1.0	23
115	Evolution and epidemiologic dynamics of dengue virus in Nicaragua during the emergence of chikungunya and Zika viruses. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104680.	1.0	6
116	Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay. <i>Journal of Immunological Methods</i> , 2021, 488, 112900.	0.6	6
117	Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000063.	1.7	5
118	Clinical neurological spectrum of adult and congenital ZIKV infection: An overview of virology, pathogenesis, and management. , 2021, , 15-28.		0
119	The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 1441-1456.	3.0	6
120	SARS-CoV-2: vaccines in the pandemic era. <i>Military Medical Research</i> , 2021, 8, 1.	1.9	104
121	The Zika virus NS1 protein as a vaccine target. , 2021, , 367-376.		0
122	Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 640190.	2.2	10
123	The Key Role of Nucleic Acid Vaccines for One Health. <i>Viruses</i> , 2021, 13, 258.	1.5	19
124	Introductory Chapter: Zika 2015-2020 - Knowledge and Experience in the Americas. , 0, , .		0
125	Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. <i>Cell</i> , 2021, 184, 881-898.	13.5	56
126	Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines. <i>Vaccine</i> , 2021, 39, 1101-1110.	1.7	8

#	ARTICLE	IF	CITATIONS
127	Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009195.	1.3	14
128	Plant-made vaccines against parasites: bioinspired perspectives to fight against Chagas disease. <i>Expert Review of Vaccines</i> , 2021, 20, 1373-1388.	2.0	5
129	Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates. <i>Vaccines</i> , 2021, 9, 307.	2.1	28
130	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 113-141.	6.6	71
131	Zika virus outbreak in Brazil—Lessons learned and perspectives for a safe and effective vaccine. <i>Anatomical Record</i> , 2021, 304, 1194-1201.	0.8	3
132	Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?. <i>Frontiers in Medical Technology</i> , 2021, 3, 640964.	1.3	4
133	Induction of protective immune responses against a lethal Zika virus challenge post-vaccination with a dual serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene. <i>Journal of General Virology</i> , 2021, 102, .	1.3	2
134	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. <i>Annals of Internal Medicine</i> , 2021, 174, 585-594.	2.0	44
135	A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage. <i>Cell Reports</i> , 2021, 35, 109107.	2.9	18
136	Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans. <i>Journal of Infectious Diseases</i> , 2021, 224, 1550-1555.	1.9	5
137	A Comparison of Zika Virus and COVID-19: Clinical Overview and Public Health Messaging. <i>Journal of Midwifery and Women's Health</i> , 2021, 66, 334-342.	0.7	12
138	Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. <i>Vaccine</i> , 2021, 39, 4108-4116.	1.7	85
139	Recent advances in mechanical force-assisted transdermal delivery of macromolecular drugs. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120598.	2.6	18
140	Identification of naturally processed Zika virus peptides by mass spectrometry and validation of memory T cell recall responses in Zika convalescent subjects. <i>PLoS ONE</i> , 2021, 16, e0252198.	1.1	9
141	Optimization of Zika DNA vaccine by delivery systems. <i>Virology</i> , 2021, 559, 10-14.	1.1	5
142	Early approval of COVID-19 vaccines: Pros and cons. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3288-3296.	1.4	14
143	Identification of potential ZIKV NS2B-NS3 protease inhibitors from <i>Andrographis paniculata</i> : An insilico approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 11203-11215.	2.0	6
144	Current development of Zika virus vaccines with special emphasis on virus-like particle technology. <i>Expert Review of Vaccines</i> , 2021, 20, 1483-1498.	2.0	8

#	ARTICLE	IF	CITATIONS
145	Cinnamic acid inhibits Zika virus by inhibiting RdRp activity. <i>Antiviral Research</i> , 2021, 192, 105117.	1.9	29
146	Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. <i>EClinicalMedicine</i> , 2021, 38, 101020.	3.2	121
147	Vaccines and treatments for Zika virus infection: patent status, triumphs and challenges. <i>Pharmaceutical Patent Analyst</i> , 2021, 10, 209-213.	0.4	2
148	Current Progress in the Development of Zika Virus Vaccines. <i>Vaccines</i> , 2021, 9, 1004.	2.1	18
149	Are the Organoid Models an Invaluable Contribution to ZIKA Virus Research?. <i>Pathogens</i> , 2021, 10, 1233.	1.2	6
150	pDNA and mRNA vaccines. , 2022, , 157-205.		1
151	Introduction to Flaviviruses and Their Global Prevalence. , 2021, , 411-439.		1
153	Long-term stability of antibody responses elicited by Dengue virus envelope DIII-based DNA vaccines. <i>Journal of General Virology</i> , 2018, 99, 1078-1085.	1.3	4
157	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. <i>Journal of Clinical Investigation</i> , 2019, 129, 4769-4785.	3.9	27
158	Vaccines for Perinatal and Congenital Infections—How Close Are We?. <i>Frontiers in Pediatrics</i> , 2020, 8, 569.	0.9	11
159	A Review on the Current Knowledge on ZIKV Infection and the Interest of Organoids and Nanotechnology on Development of Effective Therapies against Zika Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 35.	1.8	13
160	Zika virus: A global public health menace: A comprehensive update. <i>Journal of International Society of Preventive and Community Dentistry</i> , 2019, 9, 316.	0.4	11
161	Hide and Seek: The Interplay Between Zika Virus and the Host Immune Response. <i>Frontiers in Immunology</i> , 2021, 12, 750365.	2.2	16
162	Enemy of My Enemy: A Novel Insect-Specific Flavivirus Offers a Promising Platform for a Zika Virus Vaccine. <i>Vaccines</i> , 2021, 9, 1142.	2.1	9
163	Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries. <i>Vaccine</i> , 2021, 39, 7208-7219.	1.7	11
164	“They Say My Baby’s Head Is Too Small”, 2019, , 453-475.		0
165	Novel Vaccination Tools and Methods. , 2019, , 57-65.		0
167	Recent Expansion of Mosquito-Borne Pathogens Into Texas. , 2020, , 339-358.		0

#	ARTICLE	IF	CITATIONS
170	Novel suction-based in vivo cutaneous DNA transfection platform. <i>Science Advances</i> , 2021, 7, eabj0611.	4.7	17
172	Viral-vectored vaccines against SARS-CoV-2. , 2022, , 115-127.		1
173	A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity. <i>Vaccine</i> , 2021, 39, 7175-7181.	1.7	3
174	Jet injectors: Perspectives for small volume delivery with lasers. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114109.	6.6	30
175	Nonhuman Primates in Translational Research. <i>Annual Review of Animal Biosciences</i> , 2022, 10, 441-468.	3.6	11
176	Adjuvants Differentially Modulate the Immunogenicity of Lassa Virus Glycoprotein Subunits in Mice. <i>Frontiers in Tropical Diseases</i> , 2022, 3, .	0.5	0
177	DNA vaccines join the fight against COVID-19. <i>Lancet, The</i> , 2022, 399, 1281-1282.	6.3	17
178	Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 156.	2.9	15
179	Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. <i>Methods in Molecular Biology</i> , 2022, 2410, 229-263.	0.4	1
180	Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract. <i>Npj Vaccines</i> , 2022, 7, 43.	2.9	12
182	Maternal immune protection against infectious diseases. <i>Cell Host and Microbe</i> , 2022, 30, 660-674.	5.1	18
183	Self-Assembling Nanovaccine Confers Complete Protection Against Zika Virus Without Causing Antibody-Dependent Enhancement. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
184	Design of Vaccine Targeting Zika Virus Polyprotein by Immunoinformatics Technique. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, .	0.9	0
185	A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity. <i>BMC Biology</i> , 2022, 20, .	1.7	3
186	SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model. <i>Vaccines</i> , 2022, 10, 1104.	2.1	4
187	Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010588.	1.3	2
188	Novel microparticulate Zika vaccine induces a significant immune response in a preclinical murine model after intramuscular administration. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121975.	2.6	9
189	A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques. <i>Science Immunology</i> , 2022, 7, .	5.6	7

#	ARTICLE	IF	CITATIONS
191	Safety and immunogenicity of Zika virus vaccine: A systematic review of clinical trials. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	10
192	Zika Virus Vaccine: The Current State of Affairs and Challenges Posed by Antibody-Dependent Enhancement Reaction. <i>Viral Immunology</i> , 0, .	0.6	3
193	Virus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development. <i>Biologics</i> , 2022, 2, 226-242.	2.3	2
194	Current Advances in Zika Vaccine Development. <i>Vaccines</i> , 2022, 10, 1816.	2.1	27
195	Evaluation of Zika virus DNA vaccines based on NS1 and domain III of E. <i>International Immunopharmacology</i> , 2022, 113, 109308.	1.7	1
196	A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine. <i>Journal of Travel Medicine</i> , 0, .	1.4	2
197	Improved DNA Vaccine Delivery with Needle-Free Injection Systems. <i>Vaccines</i> , 2023, 11, 280.	2.1	21
198	Preclinical safety assessment of the suction-assisted intradermal injection of the SARS-CoV-2 DNA vaccine candidate pGO-1002 in white rabbit. <i>Archives of Toxicology</i> , 2023, 97, 1177-1189.	1.9	1
199	A safe replication-defective Zika virus vaccine protects mice from viral infection and vertical transmission. <i>Antiviral Research</i> , 2023, 211, 105549.	1.9	0
200	DNA A β 242 immunization via needle-less Jet injection in mice and rabbits as potential immunotherapy for Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2023, 446, 120564.	0.3	1
201	Vaccine Design Strategies: Pathogens to Genomes. , 2021, , 440-488.		0
202	Rational Development of Live-Attenuated Zika Virus Vaccines. <i>Pathogens</i> , 2023, 12, 194.	1.2	2
203	Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines. <i>Vaccines</i> , 2023, 11, 376.	2.1	0
204	Evaluation of an Engineered Zika Virus-Like Particle Vaccine Candidate in a Mosquito-Mouse Transmission Model. <i>MSphere</i> , 2023, 8, .	1.3	1
205	Zika Vaccine Microparticles (MPs)-Loaded Dissolving Microneedles (MNs) Elicit a Significant Immune Response in a Pre-Clinical Murine Model. <i>Vaccines</i> , 2023, 11, 583.	2.1	2
206	Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina. <i>Frontiers in Virology</i> , 0, 3, .	0.7	2
207	Diagnostic and vaccine potential of Zika virus envelope protein (E) derivatives produced in bacterial and insect cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
208	The Anti-Dengue Virus Peptide DV2 Inhibits Zika Virus Both In Vitro and In Vivo. <i>Viruses</i> , 2023, 15, 839.	1.5	2

#	ARTICLE	IF	CITATIONS
209	Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). Archives of Microbiology, 2023, 205, .	1.0	9
216	Zika Virus Vaccines. , 2023, , 1322-1333.e7.		0
223	Vaccines and sera. , 2024, , 15-62.		0